Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 12:30AM GMT
Release Date Price: $46.82 (-0.78%)
Ting Zhang

Good afternoon. Welcome to the 41st JPMorgan Healthcare Conference and the Blueprint Medicines presentation. My name is Ting Zhang. I'm from the JPMorgan Healthcare Investment Banking Group. It's my great pleasure to introduce Kate Haviland, CEO of Blueprint Medicines. Without further ado, Kate, take it away.

Kathryn Haviland
Blueprint Medicines Corporation - President, CEO & Director

Thank you very much, Ting, and I want to thank the entire JPMorgan team for inviting us to present today. My name is Kate Haviland. I joined Blueprint Medicines 7 years ago, and the first thing I did when I joined was come to the JPMorgan conference. And so it's a real pleasure to be here on behalf of all of the employees of Blueprint Medicines in what is our first JPMorgan presentation since we became a public company in 2015.

So I am tremendously honored to represent our team, and I have some of those team members here actually in the room, including 2 of my colleagues, our Chief Operating Officer, Christy Rossi; and our President of Research and Development,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot